Gastroenterology Clinical Trials List


Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Patients with Advanced Liver Fibrosis but Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Type of Disease:

NASH with advanced fibrosis

Locations Available:

NYU Langone Medical Center
Hepatology Associates
530 First Avenue, Suite 4J
New York, NY 10016

Principal Investigator:

Samuel Sigal, MD


Therese Capobianco


Return to the Gastroenterology Clinical Trials List.